Detection of pathological contrast enhancement with synthetic brain imaging from quantitative multiparametric MRI.
contrast enhancement
magnetic resonance imaging
quantitative transient‐state imaging
synthetic imaging
Journal
Journal of neuroimaging : official journal of the American Society of Neuroimaging
ISSN: 1552-6569
Titre abrégé: J Neuroimaging
Pays: United States
ID NLM: 9102705
Informations de publication
Date de publication:
08 Apr 2024
08 Apr 2024
Historique:
revised:
05
03
2024
received:
03
02
2024
accepted:
28
03
2024
medline:
9
4
2024
pubmed:
9
4
2024
entrez:
9
4
2024
Statut:
aheadofprint
Résumé
We aimed to test whether synthetic T1-weighted imaging derived from a post-contrast Quantitative Transient-state Imaging (QTI) acquisition enabled revealing pathological contrast enhancement in intracranial lesions. The analysis included 141 patients who underwent a 3 Tesla-MRI brain exam with intravenous contrast media administration, with the post-contrast acquisition protocol comprising a three-dimensional fast spoiled gradient echo (FSPGR) sequence and a QTI acquisition. Synthetic T1-weighted images were generated from QTI-derived quantitative maps of relaxation times and proton density. Two neuroradiologists assessed synthetic and conventional post-contrast T1-weighted images for the presence and pattern of pathological contrast enhancement in intracranial lesions. Enhancement volumes were quantitatively compared. Using conventional imaging as a reference, synthetic T1-weighted imaging was 93% sensitive in revealing the presence of contrast enhancing lesions. The agreement for the presence/absence of contrast enhancement was almost perfect both between readers (k = 1 for both conventional and synthetic imaging) and between sequences (k = 0.98 for both readers). In 91% of lesions, synthetic T1-weighted imaging showed the same pattern of contrast enhancement visible in conventional imaging. Differences in enhancement pattern in the remaining lesions can be due to the lower spatial resolution and the longer acquisition delay from contrast media administration of QTI compared to FSPGR. Overall, enhancement volumes appeared larger in synthetic imaging. QTI-derived post-contrast synthetic T1-weighted imaging captures pathological contrast enhancement in most intracranial enhancing lesions. Further comparative studies employing quantitative imaging with higher spatial resolution is needed to support our data and explore possible future applications in clinical trials.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
We aimed to test whether synthetic T1-weighted imaging derived from a post-contrast Quantitative Transient-state Imaging (QTI) acquisition enabled revealing pathological contrast enhancement in intracranial lesions.
METHODS
METHODS
The analysis included 141 patients who underwent a 3 Tesla-MRI brain exam with intravenous contrast media administration, with the post-contrast acquisition protocol comprising a three-dimensional fast spoiled gradient echo (FSPGR) sequence and a QTI acquisition. Synthetic T1-weighted images were generated from QTI-derived quantitative maps of relaxation times and proton density. Two neuroradiologists assessed synthetic and conventional post-contrast T1-weighted images for the presence and pattern of pathological contrast enhancement in intracranial lesions. Enhancement volumes were quantitatively compared.
RESULTS
RESULTS
Using conventional imaging as a reference, synthetic T1-weighted imaging was 93% sensitive in revealing the presence of contrast enhancing lesions. The agreement for the presence/absence of contrast enhancement was almost perfect both between readers (k = 1 for both conventional and synthetic imaging) and between sequences (k = 0.98 for both readers). In 91% of lesions, synthetic T1-weighted imaging showed the same pattern of contrast enhancement visible in conventional imaging. Differences in enhancement pattern in the remaining lesions can be due to the lower spatial resolution and the longer acquisition delay from contrast media administration of QTI compared to FSPGR. Overall, enhancement volumes appeared larger in synthetic imaging.
CONCLUSIONS
CONCLUSIONS
QTI-derived post-contrast synthetic T1-weighted imaging captures pathological contrast enhancement in most intracranial enhancing lesions. Further comparative studies employing quantitative imaging with higher spatial resolution is needed to support our data and explore possible future applications in clinical trials.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Health
ID : GR-2016-02361693
Informations de copyright
© 2024 The Authors. Journal of Neuroimaging published by Wiley Periodicals LLC on behalf of American Society of Neuroimaging.
Références
Smirniotopoulos JG, Murphy FM, Rushing EJ, et al. Patterns of contrast enhancement in the brain and meninges. Radiographics. 2007;27:525–551.
Weinmann HJ, Brasch RC, Press WR, et al. Characteristics of gadolinium‐DTPA complex: a potential NMR contrast agent. Am J Roentgenol. 1984;142:619–624.
Bronen RA, Sze G. Magnetic resonance imaging contrast agents: theory and application to the central nervous system. J Neurosurg. 1990;73:820–839.
Runge VM, Schaible TF, Goldstein HA, et al. Gd DTPA. Clinical efficacy. Radiographics. 1988;8:147–159.
Donahue BR, Goldberg JD, Golfinos JG, et al. Importance of MR technique for stereotactic radiosurgery. Neuro Oncol. 2003;5:268–274.
Tovi M, Lilja A, Bergström M, et al. Delineation of gliomas with magnetic resonance imaging using Gd‐DTPA in comparison with computed tomography and positron emission tomography. Acta Radiol. 1990;31:417–429.
Yoshii Y, Komatsu Y, Yamada T, et al. Malignancy and viability of intraparenchymal brain tumours: correlation between Gd‐DTPA contrast MR images and proliferative potentials. Acta Neurochir (Wien). 1992;117:187–194.
Sze G, Milano E, Johnson C, et al. Detection of brain metastases: comparison of contrast‐enhanced MR with unenhanced MR and enhanced CT. Am J Neuroradiol. 1990;11:785–791.
Ma D, Gulani V, Seiberlich N, et al. Magnetic resonance fingerprinting. Nature. 2013;495:187–192.
Gómez PA, Cencini M, Golbabaee M, et al. Rapid three‐dimensional multiparametric MRI with quantitative transient‐state imaging. Sci Rep. 2020;10:1–17.
Buonincontri G, Kurzawski JW, Kaggie JD, et al. Three dimensional MRF obtains highly repeatable and reproducible multi‐parametric estimations in the healthy human brain at 1.5T and 3T. Neuroimage. 2021;226:117573.
Peretti L, Donatelli G, Cencini M, et al. Generating synthetic radiological images with PySynthMRI: an open‐source cross‐platform tool. Tomography. 2023;9:1723–1733.
Kurzawski JW, Cencini M, Peretti L, et al. Retrospective rigid motion correction of three‐dimensional magnetic resonance fingerprinting of the human brain. Magn Reson Med. 2020;84:2606–2615.
Donatelli G, Cecchi P, Migaleddu G, et al. Quantitative T1 mapping detects blood–brain barrier breakdown in apparently non‐enhancing multiple sclerosis lesions. Neuroimage Clin. 2023;40:103509.
Som PM, Lanzieri CF, Sacher M, et al. Extracranial tumor vascularity: determination by dynamic CT scanning. Part I: concepts and signature curves. Radiology. 1985;154:401–405.
Liebner S, Fischmann A, Rascher G, et al. Claudin‐1 and claudin‐5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 2000;100:323–331.
Nduom EK, Yang C, Merrill MJ, et al. Characterization of the blood‐brain barrier of metastatic and primary malignant neoplasms. J Neurosurg. 2013;119:427–433.
Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26–41.
Long DM. Capillary ultrastructure and the blood‐brain barrier in human malignant brain tumors. J Neurosurg. 1970;32:127–144.
Engelhorn T, Schwarz MA, Eyupoglu IY, et al. Dynamic contrast enhancement of experimental glioma: an intra‐individual comparative study to assess the optimal time delay. Acad Radiol. 2010;17:188–193.
Pronin IN, McManus KA, Holodny AI, et al. Quantification of dispersion of Gd‐DTPA from the initial area of enhancement into the peritumoral zone of edema in brain tumors. J Neurooncol. 2009;94:399–408.
Wagner S, Gufler H, Eichner G, et al. Characterisation of lesions after stereotactic radiosurgery for brain metastases: impact of delayed contrast magnetic resonance imaging. Clin Oncol (R Coll Radiol). 2017;29:143–150.
Ikushima I, Korogi Y, Kuratsu J, et al. Dynamic MRI of meningiomas and schwannomas: is differential diagnosis possible? Neuroradiology. 1997;39:633–638.
Fujii K, Fujita N, Hirabuki N, et al. Neuromas and meningiomas: evaluation of early enhancement with dynamic MR imaging. Am J Neuroradiol. 1992;13:1215–1220.
Long DM. Vascular ultrastructure in human meningiomas and schwannomas. J Neurosurg. 1973;38:409–419.
Nägele T, Petersen D, Klose U, et al. The “dural tail” adjacent to meningiomas studied by dynamic contrast‐enhanced MRI: a comparison with histopathology. Neuroradiology. 1994;36:303–307.
Hawkins CP, Munro PMG, Mackenzie F, et al. Duration and selectivity of blood‐brain barrier breakdown in chronic relapsing experimental allergic encephalomyelitis studied by gadolinium‐DTPA and protein markers. Brain. 1990;113:365–378.
Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol. 1993;34:661–669.
Hashemi H, Behzadi S, Ghanaati H, et al. Evaluation of plaque detection and optimum time of enhancement in acute attack multiple sclerosis after contrast injection. Acta Radiol. 2014;55:218–224.
Gaitán MI, Shea CD, Evangelou IE, et al. Evolution of the blood‐brain barrier in newly forming multiple sclerosis lesions. Ann Neurol. 2011;70:22–29.
Fishman RA, Dillon WP. Dural enhancement and cerebral displacement secondary to intracranial hypotension. Neurology. 1993;43:609–609.